Skip to main content
OpenTrials
Completed

NCT Number: NCT01821872

Paracetamol CSF Pharmacokinetics Study

Despite its use for decades all over the world, the exact mechanism of action of paracetamol is not fully understood and essentially involves a combination of hypotheses. It is known to have an effect via the central nervous system, and of the many mechanisms proposed, one hypothesis is that it may have indirectly activate CB1 (cannabinoid) receptors, through its novel metabolite AM404.

This study aims to elucidate cerebrospinal levels of paracetamol and to measure the concentration of its metabolites, including AM404 in CSF. This may, in turn, give us useful information on the mechanism of action of paracetamol.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

St Bartholomew's Hospital

London, EC1A, United Kingdom

About this study

Patients undergoing spinal blockade for urological surgery were administered 1g paracetamol intravenously at varying intervals prior to spinal anaesthesia, at which time 5mls of cerebrospinal fluid and 10mls of blood were sampled, and analysed for concentrations of paracetamol, paracetamol glucuronide, paracetamol sulphate, and AM404, a known endocannabinoid reuptake inhibitor, and metabolite of paracetamol.

Paracetamol readily penetrates into the cerebrospinal fluid in animal studies and in children. This could account for the rapid central analgesic and antipyretic action of intravenous paracetamol however this remains to be studied in adults. AM404 has never before been identified in humans, and its presence in CSF following paracetamol supports the hypothesis of a central mechanism of action of paracetamol via AM404.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult subjects aged 18 to 80 years
  • Subjects undergoing surgery who require a spinal anaesthetic and paracetamol as part of their routine anaesthetic plan
  • Subjects with an American Society of Anesthesiology score of I-III

Exclusion criteria

  • Subjects with any contraindication to spinal anaesthesia
  • Subjects with known clotting abnormalities
  • Pregnant or lactating women
  • Subjects with known hypersensitivity to paracetamol
  • Patients with severe hepatocellular insufficiency
  • Patients already taking regular doses of paracetamol
  • Any subjects deemed medically unsuitable by the investigator

Treatment and study plan

Administration of paracetamol

Drug

Administration of 1g intravenous paracetamol

Other names: Perfalgan

Primary outcomes

  1. Measurement of AM404 in CSF

    Time frame: 5-211 minutes post-administration of paracetamol

    AM404 is a metabolite of paracetamol thought to be formed in the brain.

Secondary outcomes

  1. Measurement of paracetamol in plasma and CSF

    Time frame: 5-211 minutes post administration of paracetamol

    Concentrations of paracetamol measured in plasma and CSF following intravenous paracetamol administration.

  2. Measurement of paracetamol glucuronide and sulphate conjugates in plasma and CSF.

    Time frame: 5-211 minutes post administration of paracetamol

    Concentrations of glucuronide and sulphate conjugates of paracetamol measured in plasma and CSF following intravenous paracetamol administration.

Sponsors and collaborators

Lead sponsor

Barts & The London NHS Trust

Other

Registry information

Official study title

A Single Centre Prospective Randomised Study to Investigate the Cerebrospinal Fluid (CSF) Pharmacokinetics of Intravenous Paracetamol in Humans

Important dates

Study start
2011
Primary completion
2011
Study completion
2011
First posted
Apr 1, 2013
Registry last updated
Apr 4, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.